Compugen (CGEN) Receivables (2009 - 2024)

Compugen (CGEN) reported Receivables of $5.0 million for Q2 2024, down 91.8% sequentially from $61.0 million in Q4 2023.

Compugen (CGEN) Receivables (2009 - 2024) Analysis & Trends

Compugen (CGEN) has 10 years of Receivables data on file, last reported at $5.0 million in Q2 2024.

For the quarter ending Q2 2024, Receivables changed N/A year-over-year to $5.0 million; the trailing twelve-month figure through Jun 2024 stood at $5.0 million (changed N/A YoY), and the FY2023 full-year result was $61.0 million, changed N/A from the prior year.
Receivables retreated to $5.0 million in Q2 2024, from $61.0 million in the prior quarter.
In the past five years, Receivables ranged from a high of $61.0 million in Q4 2023 to a low of $2.0 million in Q4 2020.
A 4-year average of $18.5 million and a median of $5.5 million in 2021 frame the typical range for Receivables.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Receivables (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	4.97 Mn
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	938.02 Mn
4	NuCana	279.75 Bn	279.75 Bn	-	1.13 Mn
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	2.00 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	5.73 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	1.93 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	Compugen	221.26 Mn	129.51 Mn	352,000.00	-

Download Data